Skip to main content
Journal cover image

Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Publication ,  Conference
Liu, Z; Xu-Monette, ZY; Cao, X; Visco, C; Tzankov, A; Montes-Moreno, S; Dybkær, K; Chiu, A; Orazi, A; Zu, Y; Bhagat, G; Richards, KL; Hsi, ED ...
Published in: Clinical Lymphoma Myeloma and Leukemia
June 2015

Duke Scholars

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

June 2015

Volume

15

Start / End Page

S216 / S216

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liu, Z., Xu-Monette, Z. Y., Cao, X., Visco, C., Tzankov, A., Montes-Moreno, S., … Young, K. H. (2015). Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. In Clinical Lymphoma Myeloma and Leukemia (Vol. 15, pp. S216–S216). Elsevier BV. https://doi.org/10.1016/j.clml.2015.04.087
Liu, Zhiyu, Zijun Y. Xu-Monette, Xin Cao, Carlo Visco, Alexander Tzankov, Santiago Montes-Moreno, Karen Dybkær, et al. “Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S216–S216. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.087.
Liu Z, Xu-Monette ZY, Cao X, Visco C, Tzankov A, Montes-Moreno S, et al. Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S216–S216.
Liu, Zhiyu, et al. “Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, Elsevier BV, 2015, pp. S216–S216. Crossref, doi:10.1016/j.clml.2015.04.087.
Liu Z, Xu-Monette ZY, Cao X, Visco C, Tzankov A, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, Han van Krieken J, Huh J, Ai W, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S216–S216.
Journal cover image

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

June 2015

Volume

15

Start / End Page

S216 / S216

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences